Cancer stem cells(CSCs) are a small subset of cells in cancers that are thought to initiate tumorous transformation and promote metastasis, recurrence, and resistance to treatment. Growing evidence has revealed the ex...Cancer stem cells(CSCs) are a small subset of cells in cancers that are thought to initiate tumorous transformation and promote metastasis, recurrence, and resistance to treatment. Growing evidence has revealed the existence of CSCs in various types of cancers and suggested that CSCs differentiate into diverse lineage cells that contribute to tumor progression. We may be able to overcome the limitations of cancer treatment with a comprehensive understanding of the biological features and mechanisms underlying therapeutic resistance in CSCs. This review provides an overview of the properties, biomarkers, and mechanisms of resistance shown by CSCs. Recent findings on metabolic features, especially fatty acid metabolism and ferroptosis in CSCs, are highlighted, along with promising targeting strategies. Targeting CSCs is a potential treatment plan to conquer cancer and prevent resistance and relapse in cancer treatment.展开更多
Non-small cell lung cancer(NSCLC)patients with Kirsten rat sarcoma viral oncogene homolog(KRAS)mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as s...Non-small cell lung cancer(NSCLC)patients with Kirsten rat sarcoma viral oncogene homolog(KRAS)mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as surgical resection,radiotherapy,chemotherapies,and targeted medicines.However,the application of immune checkpoints inhibitors(ICIs)has dramatically altered the therapeutic pattern of NSCLC management.Clinical studies have indicated that some KRAS-mutant NSCLC patients could benefit from ICIs;however,the responses in some patients are still poor.This review intends to elucidate the mechanisms of resistance to immunotherapy in KRAS-driven NSCLC and highlight the TME functions altered by immunoinhibitors,immunostimulators,and cancer metabolism.These metabolic pathways could potentially be promising approaches to overcome immunotherapy resistance.展开更多
基金supported by the National Key Research and Development Program of China (Grant No.2023YFC3402100)the National Natural Science Foundation of China (Grant No.92259102)。
文摘Cancer stem cells(CSCs) are a small subset of cells in cancers that are thought to initiate tumorous transformation and promote metastasis, recurrence, and resistance to treatment. Growing evidence has revealed the existence of CSCs in various types of cancers and suggested that CSCs differentiate into diverse lineage cells that contribute to tumor progression. We may be able to overcome the limitations of cancer treatment with a comprehensive understanding of the biological features and mechanisms underlying therapeutic resistance in CSCs. This review provides an overview of the properties, biomarkers, and mechanisms of resistance shown by CSCs. Recent findings on metabolic features, especially fatty acid metabolism and ferroptosis in CSCs, are highlighted, along with promising targeting strategies. Targeting CSCs is a potential treatment plan to conquer cancer and prevent resistance and relapse in cancer treatment.
基金supported by research grants from the National Natural Science Foundation of China(No.81873048)Sichuan Provincial Science Fund for Distinguished Young Scholars of China(2020JDJQ0065).
文摘Non-small cell lung cancer(NSCLC)patients with Kirsten rat sarcoma viral oncogene homolog(KRAS)mutation are associated with significant clinical heterogeneity and a poor prognosis to standard NSCLC therapies such as surgical resection,radiotherapy,chemotherapies,and targeted medicines.However,the application of immune checkpoints inhibitors(ICIs)has dramatically altered the therapeutic pattern of NSCLC management.Clinical studies have indicated that some KRAS-mutant NSCLC patients could benefit from ICIs;however,the responses in some patients are still poor.This review intends to elucidate the mechanisms of resistance to immunotherapy in KRAS-driven NSCLC and highlight the TME functions altered by immunoinhibitors,immunostimulators,and cancer metabolism.These metabolic pathways could potentially be promising approaches to overcome immunotherapy resistance.